126
126
Aug 5, 2016
08/16
by
BLOOMBERG
tv
eye 126
favorite 0
quote 0
let's look at bristol-myers squibb and merck, these two are moving in tandem with each other. the news at of bristol-myers squibb is that its lung cancer drug failed in a late stage trial. that's why shares or falling. merck competes with bristol-myers squibb in that same area, and for its drug it has seen positivity, which is why shares are up nearly 7%. let's move on to know nordisk. this is the world -- novo nordisk. this is the world's biggest insulin maker, with a 50% share of the world's supply, but insulin shares or falling in shares are looking at the biggest drop in the last three and a half years, down more than 10%. finally, let's look at earnings regeneron and x-ray, both shares at their lowest in the past few weeks. scarlet: good stuff. thank you so much. let's check in on the bloomberg first word news. mark crumpton has more from our newsroom. mark: there is a racial divide among young americans over hillary clinton's use of a private e-mail server while she was secretary of state. most young whites say she intentionally broke the law, but young minorities are mor
let's look at bristol-myers squibb and merck, these two are moving in tandem with each other. the news at of bristol-myers squibb is that its lung cancer drug failed in a late stage trial. that's why shares or falling. merck competes with bristol-myers squibb in that same area, and for its drug it has seen positivity, which is why shares are up nearly 7%. let's move on to know nordisk. this is the world -- novo nordisk. this is the world's biggest insulin maker, with a 50% share of the world's...
131
131
Aug 5, 2016
08/16
by
BLOOMBERG
tv
eye 131
favorite 0
quote 0
as well as bristol-myers squibb moving in tandem. merck is up by 6%. the reason is because of bristol-myers squib. they said their lung cancer drug failed in late stage trials. merck has another cancer drug that is actually competitor for that. up by 5%, raising its full-year sales forecast there. and priceline up by 5%. second-quarter profit beat estimates because the number of hotel rooms booked across all its websites has been growing. interestingly, we were talking about the terror attacks in europe, that has had a muted effect on priceline. vonnie: fascinating. let's check in now on the first word news this morning. courtney collins has more. courtney: donald trump is dropping his claim that he saw video of the u.s. cash payment going to iran. the republican presidential nominee posted a tweet today saying "the plane i saw on television was the hostage plane in geneva switzerland. not the plane carrying $400 million in cash going to iran." trump said he saw video of the money being delivered. news conference at the pentagon yesterday, president oba
as well as bristol-myers squibb moving in tandem. merck is up by 6%. the reason is because of bristol-myers squib. they said their lung cancer drug failed in late stage trials. merck has another cancer drug that is actually competitor for that. up by 5%, raising its full-year sales forecast there. and priceline up by 5%. second-quarter profit beat estimates because the number of hotel rooms booked across all its websites has been growing. interestingly, we were talking about the terror attacks...
102
102
Aug 5, 2016
08/16
by
BLOOMBERG
tv
eye 102
favorite 0
quote 0
this has to be with bristol-myers squibb, down 17%. it turns out its lung cancer drug failed in late-stage trials. they were hoping for it to be a first-line cancer drug. this actually accounts for about 17% of bristol-myers squibb's revenue. on the flip side of that, look at this, merck is up. it had a pop of 11%. the reason it's popping is because its drug competes in second-line treatment. we're seeing a little bit of give and take there. let's get on to earnings. priceline.com reported their second-quarter profit, up by more than 5% here. it turns out the number of hotel room booked across its website is growing. it says that the gross travel bookings that it saw jumped 19%, to nearly $18 billion. the expectation year-on-year was $15 billion or so. also, let's move on over to rack space hosting. this is a cloud computing service. look at this, up nearly 11% here, rallying the most in two years as of yesterday, still continuing that trend. "the wall street journal" is reporting that it's nearing a deal that it could be taken over by
this has to be with bristol-myers squibb, down 17%. it turns out its lung cancer drug failed in late-stage trials. they were hoping for it to be a first-line cancer drug. this actually accounts for about 17% of bristol-myers squibb's revenue. on the flip side of that, look at this, merck is up. it had a pop of 11%. the reason it's popping is because its drug competes in second-line treatment. we're seeing a little bit of give and take there. let's get on to earnings. priceline.com reported...
71
71
Aug 6, 2016
08/16
by
KQED
tv
eye 71
favorite 0
quote 0
. >> bristol myers squibb made a risky bet and lost. one of the company's most promising and best-selling cancer treatments failed in a trial for patients with the most common form of newly diagnosed lung cancer. bristol wanted this therapy to broaden oud and used a risky research strategy. that sent shares plumeting 16%, wiping out about $20 billion of bristol's market value, but this setback may not be as bad as it seem >> the save three trial failure is a blow to bristol myers squib and patients. still, some say things are aren't hopeless. >> i think bristol's down a little much. you would believe that the story today in long cancer for this particular drug from bristol myers, would never again raise its head in lung cancer. that's to say there would be no hope for bristol myers to be in lung cancer in the future and my sense is that's probably incorrect. >> news was a win for merck, who's competing drug succeed ed in a son s w shooting for a home run. trying to use an already successful cancer drug the to take on lung cancer. one of
. >> bristol myers squibb made a risky bet and lost. one of the company's most promising and best-selling cancer treatments failed in a trial for patients with the most common form of newly diagnosed lung cancer. bristol wanted this therapy to broaden oud and used a risky research strategy. that sent shares plumeting 16%, wiping out about $20 billion of bristol's market value, but this setback may not be as bad as it seem >> the save three trial failure is a blow to bristol myers...
111
111
Aug 5, 2016
08/16
by
BLOOMBERG
tv
eye 111
favorite 0
quote 0
we saw bristol-myers squibb being dealt a setback on a drug they had for lunch answer.xplain what that means for the company? how big of a setback is that with the face they place in immunotherapy? dr. cosgrove: immunotherapy has tremendous potential. we've seen it in things like melanoma, which has been very exciting therapy. .e're looking at a new era i think that will be productive over the years. failed,ause one drug is i don't think you're going to see this abandoned or everybody pull away from that particular. cosgrove joining us in new york. still ahead on "bloomberg markets," will valeant be able to sacrifice its way to success? this is bloomberg. ♪ david: this is "bloomberg markets," i'm david gura. vonnie: i'm vonnie quinn. a look at some of the biggest business stories in the news right now. mergerse overseeing two among four health insurers is giving up on one of them. that includes rulings on both by the end of the year. there's a chance that it fall apart before hand. u.s. district judge is giving the case against aetna's deal for humana. making the challe
we saw bristol-myers squibb being dealt a setback on a drug they had for lunch answer.xplain what that means for the company? how big of a setback is that with the face they place in immunotherapy? dr. cosgrove: immunotherapy has tremendous potential. we've seen it in things like melanoma, which has been very exciting therapy. .e're looking at a new era i think that will be productive over the years. failed,ause one drug is i don't think you're going to see this abandoned or everybody pull away...
127
127
Aug 5, 2016
08/16
by
MSNBCW
tv
eye 127
favorite 0
quote 0
one stock not participating in today's rally bristol-myers squibb. company's experimental lung cancer drug failed in a clinical trial. shares slid about 16% today. that's it from cnbc, first in business worldwide. it's the little things in life that make me smile. spending the day with my niece. i don't use super poligrip for hold, because my dentures fit well. before those little pieces would get in between my dentures and my gum and it was uncomfortable. even well fitting dentures let in food particles. just a few dabs of super poligrip free is clinically proven to seal out more food particles so you're more comfortable and confident while you eat. so it's not about keeping my dentures in, it's about keeping the food particles out. try super poligrip free. >>> having spent time around this good man since this add n adventure began for my family, there's one thing i know for sure, when donald trump becomes president of the united states of america, the change will be huge! >> huge. no one can say mike pence hasn't been a loyal running mate. there he
one stock not participating in today's rally bristol-myers squibb. company's experimental lung cancer drug failed in a clinical trial. shares slid about 16% today. that's it from cnbc, first in business worldwide. it's the little things in life that make me smile. spending the day with my niece. i don't use super poligrip for hold, because my dentures fit well. before those little pieces would get in between my dentures and my gum and it was uncomfortable. even well fitting dentures let in food...
161
161
Aug 8, 2016
08/16
by
BLOOMBERG
tv
eye 161
favorite 0
quote 3
oil on the upside, bristol-myers squibb falling again today after plunging friday on a negative results of a study on a drug to treat lung cancer. that has a lot of analyst commentary. pfizer and allergan, even though their profit beat estimates, sales missed estimates. oliver: we have the olympics in full swing after this weekend. what is happening in brazilian markets? julie: they have been doing well this year. i was talking to michael regan about etf's. here is the brazilian benchmark. the five-day action trading at its highest since last may. all year we have seen a gain in brazilian stocks on the political turmoil we have seen their. now there is an acting temer, butmichel there are questions now has to participation in some of the things that got doma rosato out of office. if you look at some of the stocks go to most, petrobras. the oil producer is rising more than 3.5% along with oil. other commodities coming out of brazil are also active, although this time to the downside. orange juice and coffee are that is notday, but putting much of a dent in the stock rally. scarlet: thank
oil on the upside, bristol-myers squibb falling again today after plunging friday on a negative results of a study on a drug to treat lung cancer. that has a lot of analyst commentary. pfizer and allergan, even though their profit beat estimates, sales missed estimates. oliver: we have the olympics in full swing after this weekend. what is happening in brazilian markets? julie: they have been doing well this year. i was talking to michael regan about etf's. here is the brazilian benchmark. the...
88
88
tv
eye 88
favorite 0
quote 0
quickly bristol-myers squibb down 5%. cancer drug fails. let's get you back to "coast to coast."e of high-tech thieves in texas. they have been out there stealing cars and doing so with their laptops, using laptop computers to steal cars. adam shapiro is with us now from the newsroom. give us the details on this, adam. reporter: i want to show you video. because they caught the thieves red-handed. here is what is going on. they were able to use laptop to break into certain jeep vehicles as well as dodge pickup trucks, starthe vehicles using the laptop and then taking advantage of the software within the car, then drive it away, they were taking them to mexico. so we got a statement from fiat chrysler. what they told us, this is a quote, fiat chrysler takes the safety and security of its customers seriously, quote and incorporates security features in its vehicles that help to reduce the risk of unauthorized and unlawful access to vehicle systems and wireless communications. houston police after getting several complaint about this and tip from homeland security, department of hom
quickly bristol-myers squibb down 5%. cancer drug fails. let's get you back to "coast to coast."e of high-tech thieves in texas. they have been out there stealing cars and doing so with their laptops, using laptop computers to steal cars. adam shapiro is with us now from the newsroom. give us the details on this, adam. reporter: i want to show you video. because they caught the thieves red-handed. here is what is going on. they were able to use laptop to break into certain jeep...
118
118
Aug 5, 2016
08/16
by
BLOOMBERG
tv
eye 118
favorite 0
quote 0
bristol-myers. bristol-myers squibb's main cancer drug. report its study. it showed up negative, and we have some criticism as to why it showed up negative. there were certain cut off that they should have used. this was very unexpected. they thought they had was thise in the ba. david: they have substantial revenues, not hundred million dollars in revenue. this was a question whether it could be used for more people in other applications, correct? >> it is now used to treat four or five different types of cancer. one was going to be used cancer,tline lung the first drug you take when you are diagnosed with lung cancer. lung cancer is among the top three types of cancers in the world. david: it was projected to go, to $7 billion. does this mean that is not going to happen? >> $7 billion seemed to be a bit of a stretch. but as a combination therapy, they missed on this drug as a single agent. they still have other drugs coming further down the line. this means that compared to merck, they have this golden opportunity because they will that
bristol-myers. bristol-myers squibb's main cancer drug. report its study. it showed up negative, and we have some criticism as to why it showed up negative. there were certain cut off that they should have used. this was very unexpected. they thought they had was thise in the ba. david: they have substantial revenues, not hundred million dollars in revenue. this was a question whether it could be used for more people in other applications, correct? >> it is now used to treat four or five...
135
135
Aug 5, 2016
08/16
by
CNBC
tv
eye 135
favorite 0
quote 0
we'll talk about bristol-myers squibb disappointing cancer drug trial and why merck is popping as a result today. >>> as donald trump unveils the economic team ahead of a policy speech in detroit monday, a key member speaks with us along with an informal economic adviser to hillary clinton. there may be some fireworks. ♪ mapping the oceans. where we explore. protecting biodiversity. everywhere we work. defeating malaria. improving energy efficiency. developing more clean burning natural gas. my job? my job at exxonmobil? turning algae into biofuels. reducing energy poverty in the developing world. making cars go further with less. fueling the global economy. and you thought we just made the gas. ♪ energy lives here. it'slexus performance iny to street-legal form.taking for a limited time get great offers on our complete line of f sport performance vehicles. at the lexus golden opportunity sales event. >>> rally day after the jobs report. almost 1 on the dow. the s&p up 17. that's in record territory, by the way. and the nasdaq is in record territory right now. isn't it? yes. >> pretty much
we'll talk about bristol-myers squibb disappointing cancer drug trial and why merck is popping as a result today. >>> as donald trump unveils the economic team ahead of a policy speech in detroit monday, a key member speaks with us along with an informal economic adviser to hillary clinton. there may be some fireworks. ♪ mapping the oceans. where we explore. protecting biodiversity. everywhere we work. defeating malaria. improving energy efficiency. developing more clean burning...